Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of accelerated one-strength Allergovit Birch dose escalation versus standard two-strength escalation
2021-002317-34Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of birch pollen allergoid in seasonal allergic rhinitis (SAR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Allergopharma. Primary endpoint: Descriptive safety variables. Started Nov 2021; status: completed.
02
Drugs
birch pollen allergoid
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2021-002317-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002317-34.